The attached article outlines the current state of treatment for Osteosarcoma (the most common childhood bone sarcoma). A historical perspective is included and a nice flow sheet outlining current and future directions for improving outcomes. Ongoing research is working on increasing 5-year survival rates above the 60-70% for extremity non-metastatic disease and offering better options for treatment for recurrent or metastatic disease.